Development of prostaglandin D 2 receptor antagonist: Discovery of highly potent antagonists

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 17, 2004, Pages 4685-4700

  Torisu, Kazuhiko ^a   Kobayashi, Kaoru ^a   Iwahashi, Maki ^a   Nakai, Yoshihiko ^a   Onoda, Takahiro ^a   Nagase, Toshihiko ^a   Sugimoto, Isamu ^a   Okada, Yutaka ^a   Matsumoto, Ryoji ^a   Nanbu, Fumio ^a   Ohuchida, Shuichi ^a   Nakai, Hisao ^a   Masaaki Toda, ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

Author keywords

Antagonist; DP receptor; Prostaglandin

Indexed keywords

[1 [4 (2 ETHOXYETHOXY)BENZOYL] 2 METHYL 1H INDOL 4 YL]ACETIC ACID; [1 [4 (2 ISOPROPOXYETHOXY)BENZOYL] 2 METHYL 1H INDOL 4 YL]ACETIC ACID; [1 [4 (3 ETHOXYPROPOXY)BENZOYL] 2 METHYL 1H INDOL 4 YL]ACETIC ACID; [1 [4 (HEXYLOXY)BENZOYL] 2 METHYL 1H INDOL 4 YL]ACETIC ACID; [1 [4 [2 (2 METHOXYETHOXY)ETHOXY]BENZOYL] 2 METHYL 1H INDOL 4 YL]ACETIC ACID; [1 [4 [2 (ETHYLTHIO)ETHOXY]BENZOYL] 2 METHYL 1H INDOL 4 YL]ACETIC ACID; [2 METHYL 1 [4 (2 PHENOXYETHOXY)BENZOYL] 1H INDOL 4 YL]ACETIC ACID; [2 METHYL 1 [4 (2 PROPOXYETHOXY)BENZOYL] 1H INDOL 4 YL]ACETIC ACID; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT; CYCLIC AMP; IMMUNOGLOBULIN RECEPTOR; INDOLEACETIC ACID DERIVATIVE; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; MOUSE; NONHUMAN; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; METABOLISM; SYNTHESIS;

ANTI-ALLERGIC AGENTS; BINDING SITES; CYCLIC AMP; DRUG DESIGN; INDOLEACETIC ACIDS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3843125292     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.06.024     Document Type: Article

References (12)

1. R.A. Coleman Prostanoids Receptors D. Girdlestne The IUPHAR Compendium of Receptor Characterization and Classification 1998 Burlington Cambridge 229 244
2. R.A. Coleman, W.L. Smith, and S. Narumiya Pharmacol. Rev. 46 1994 205 229
3. S. Narumiya, Y. Sugimoto, and F. Ushikubi Physiol. Rev. 79 1999 1193 1226
4. S. Mitsumori, T. Tsuri, T. Honma, Y. Hiramatsu, T. Okada, H. Hashizume, M. Inagaki, A. Arimura, K. Yasui, F. Asanuma, J. Kishino, and M. Ohtani J. Med. Chem. 46 2003 2436 2445
5. S. Mitsumori, T. Tsuri, T. Honma, Y. Hiramatsu, T. Okada, H. Hashizume, M. Inagaki, A. Arimura, K. Yasui, F. Asanuma, J. Kishino, and M. Ohtani J. Med. Chem. 46 2003 2446 2455
6. Torisu, K.; Kobayashi, K.; Iwahashi, M.; Egashira, H.; Nakai, Y.; Okada, Y.; Nanbu, F.; Ohuchida, S.; Nakai, H.; Toda, M. Bioorg. Med. Chem. Lett., accepted for publication. DOI:10.1016/j.bmcl.2004.06.006
7. H.J. Knoelker, and Knoell J. Chem. Commun. 10 2003 1170 1171
8. S. Cacchi, P.G. Ciattini, E. Morera, and G. Ortar Tetrahedron Lett. 27 1986 3931
9. V. Lee, and M.S. Newman Org. Synth. 50 1970 77
10. T. Aoyama, and T. Shioiri Chem. Pharm. Bull. 29 1981 3249
11. N.A. Powell, and S.D. Rychnovsky Tetrahedron Lett. 37 1996 7901 7904
12. M. Kiriyama, F. Ushikubi, T. Kobayashi, M. Hirata, Y. Sugimoto, and S. Narumiya Br. J. Pharmacol. 122 1997 217 224